신경 내분비성 전립선암 시장 보고서(2026년)

Neuroendocrine prostate cancer is a rare and aggressive prostate cancer subtype marked by neuroendocrine cells that influence tumor growth and resistance to conventional treatments. This condition can occur de novo or arise after long-term androgen deprivation therapy in prostate cancer patients. Treatment options include chemotherapy, targeted therapy, immunotherapy, and supportive care to manage symptoms and improve patient outcomes.

The primary types of neuroendocrine prostate cancer treatment include chemotherapy and hormonal therapy. Chemotherapy refers to the administration of cytotoxic medications to destroy or suppress the growth of cancerous cells within the prostate. These treatments are also available as therapeutic options including immunotherapy and targeted therapy. They are applied across disease stages such as localized disease, advanced disease, and metastatic disease, and are utilized by end users including hospitals, oncology specialty clinics, and cancer research institutes.

Tariffs on oncology drugs, biologics inputs, and diagnostic reagents are impacting the neuroendocrine prostate cancer market by increasing treatment and testing costs. Imported chemotherapeutic agents and specialized diagnostic kits are the most affected segments. Countries that rely heavily on imported oncology supplies face higher therapy pricing and budget pressure. These cost increases can affect access in cost sensitive healthcare systems. At the same time, tariffs are encouraging domestic oncology drug manufacturing and local diagnostic kit production.

The neuroendocrine prostate cancer market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine prostate cancer market statistics, including neuroendocrine prostate cancer industry global market size, regional shares, competitors with a neuroendocrine prostate cancer market share, detailed neuroendocrine prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine prostate cancer industry. This neuroendocrine prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuroendocrine prostate cancer market size has grown strongly in recent years. It will grow from $1.05 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rise in prostate cancer diagnosis, long term hormone therapy resistance, expansion of oncology drug pipelines, growth of molecular pathology testing, increased cancer center specialization.

The neuroendocrine prostate cancer market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth of precision oncology adoption, rising biomarker based treatment, expansion of targeted therapies, increased rare cancer research funding, broader genomic testing use. Major trends in the forecast period include biomarker driven patient stratification, combination oncology therapy protocols, advanced molecular diagnostic testing, rare cancer clinical trial expansion, targeted radiopharmaceutical approaches.

The growing prevalence of prostate cancer is expected to drive the growth of the neuroendocrine prostate cancer market in the coming years. Prostate cancer is a malignant tumor that develops in the prostate gland, primarily affecting men over 50 years of age. The prevalence of prostate cancer is increasing mainly due to the expanding aging male population, as advancing age is a key risk factor for disease development. The prevalence of prostate cancer supports the growth of neuroendocrine prostate cancer by enlarging the overall patient pool, increasing long-term exposure to androgen-deprivation therapies, and thereby raising the likelihood of treatment-induced neuroendocrine differentiation in advanced and castration-resistant stages of the disease. For instance, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, reported that in 2023 there were 255,395 new cases of prostate cancer diagnosed in the United States, with 33,881 men succumbing to the disease. Therefore, the increasing prevalence of prostate cancer is driving the growth of the neuroendocrine prostate cancer market.

Organizations operating in the neuroendocrine prostate cancer market are focusing on developing innovative drugs such as immune-modulating small-molecule therapies to enhance immune response and improve patient outcomes. Immune-modulating small-molecule therapies are orally administered compounds that stimulate the body's innate immune system to recognize and attack cancer cells, helping overcome resistance to traditional treatments such as hormone therapy or chemotherapy by enhancing the anti-tumor immune response. For example, in February 2024, BioXcel Therapeutics, a US-based clinical-stage biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration for BXCL701, an immune-modulating small-molecule therapy for neuroendocrine prostate cancer. BXCL701 is designed to activate the NLRP3 inflammasome, increase cytokine release, and prime the immune system to target tumor cells, offering a novel approach that complements immune checkpoint inhibitors. The Fast Track Designation is expected to accelerate the clinical development and regulatory review of BXCL701, reflecting its potential to address significant unmet medical needs in aggressive and treatment-resistant prostate cancer.

In March 2024, Merck & Co. Inc., a US-based healthcare and biopharmaceutical company, acquired Harpoon Therapeutics, Inc. for an undisclosed sum. This acquisition enables Merck & Co., Inc. to expand and diversify its oncology pipeline by strengthening its portfolio of innovative T-cell engagers for advanced cancers. Harpoon Therapeutics Inc. is a US-based biotechnology company that develops pioneering T-cell engager therapies for cancers including small cell lung cancer, neuroendocrine prostate cancer, and multiple myeloma.

Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.

North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuroendocrine prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroendocrine prostate cancer market consists of revenues earned by entities by providing services such as advanced diagnostic and pathological testing, molecular and biomarker analysis, oncological consultations, personalized treatment planning, and administration and monitoring of systemic therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine prostate cancer market also includes sales of chemotherapeutic agents, hormone therapy-resistant drugs, radiopharmaceuticals, diagnostic kits and biomarker assays, and supportive oncology medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroendocrine Prostate Cancer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neuroendocrine prostate cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroendocrine prostate cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuroendocrine prostate cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment: Chemotherapy; Hormonal Therapy
• 2) By Therapeutics: Immunotherapy; Targeted Therapy
• 3) By Disease Stage: Localized Disease; Advanced Disease; Metastatic Disease
• 4) By End Users: Hospitals; Oncology Specialty Clinics; Cancer Research Institutes
• Subsegments:
• 1) By Chemotherapy: Platinum Based Chemotherapy; Taxane Based Chemotherapy; Combination Chemotherapy; Second Line Chemotherapy
• 2) By Hormonal Therapy: Androgen Deprivation Therapy; Androgen Receptor Inhibition; Hormone Synthesis Inhibition; Combined Hormonal Therapy
• Companies Mentioned: Novartis AG; Amgen Inc.; Phanes Therapeutics Inc.; and BioXcel Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Neuroendocrine Prostate Cancer Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Neuroendocrine Prostate Cancer Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Neuroendocrine Prostate Cancer Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Neuroendocrine Prostate Cancer Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Biomarker Driven Patient Stratification
  • 4.2.2 Combination Oncology Therapy Protocols
  • 4.2.3 Advanced Molecular Diagnostic Testing
  • 4.2.4 Rare Cancer Clinical Trial Expansion
  • 4.2.5 Targeted Radiopharmaceutical Approaches

5. Neuroendocrine Prostate Cancer Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Specialty Clinics
• 5.3 Cancer Research Institutes
• 5.4 Academic Medical Centers
• 5.5 Specialty Diagnostic Laboratories

6. Neuroendocrine Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neuroendocrine Prostate Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Neuroendocrine Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Neuroendocrine Prostate Cancer Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Neuroendocrine Prostate Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Neuroendocrine Prostate Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neuroendocrine Prostate Cancer Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neuroendocrine Prostate Cancer Market Segmentation

• 9.1. Global Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapy, Hormonal Therapy
• 9.2. Global Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunotherapy, Targeted Therapy
• 9.3. Global Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Localized Disease, Advanced Disease, Metastatic Disease
• 9.4. Global Neuroendocrine Prostate Cancer Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Oncology Specialty Clinics, Cancer Research Institutes, Academic Medical Centers
• 9.5. Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Platinum Based Chemotherapy, Taxane Based Chemotherapy, Combination Chemotherapy, Second Line Chemotherapy
• 9.6. Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Androgen Deprivation Therapy, Androgen Receptor Inhibition, Hormone Synthesis Inhibition, Combined Hormonal Therapy

10. Neuroendocrine Prostate Cancer Market Regional And Country Analysis

• 10.1. Global Neuroendocrine Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Neuroendocrine Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neuroendocrine Prostate Cancer Market

• 11.1. Asia-Pacific Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neuroendocrine Prostate Cancer Market

• 12.1. China Neuroendocrine Prostate Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neuroendocrine Prostate Cancer Market

• 13.1. India Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neuroendocrine Prostate Cancer Market

• 14.1. Japan Neuroendocrine Prostate Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neuroendocrine Prostate Cancer Market

• 15.1. Australia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neuroendocrine Prostate Cancer Market

• 16.1. Indonesia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neuroendocrine Prostate Cancer Market

• 17.1. South Korea Neuroendocrine Prostate Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neuroendocrine Prostate Cancer Market

• 18.1. Taiwan Neuroendocrine Prostate Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neuroendocrine Prostate Cancer Market

• 19.1. South East Asia Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neuroendocrine Prostate Cancer Market

• 20.1. Western Europe Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neuroendocrine Prostate Cancer Market

• 21.1. UK Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neuroendocrine Prostate Cancer Market

• 22.1. Germany Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neuroendocrine Prostate Cancer Market

• 23.1. France Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neuroendocrine Prostate Cancer Market

• 24.1. Italy Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neuroendocrine Prostate Cancer Market

• 25.1. Spain Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neuroendocrine Prostate Cancer Market

• 26.1. Eastern Europe Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neuroendocrine Prostate Cancer Market

• 27.1. Russia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neuroendocrine Prostate Cancer Market

• 28.1. North America Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neuroendocrine Prostate Cancer Market

• 29.1. USA Neuroendocrine Prostate Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neuroendocrine Prostate Cancer Market

• 30.1. Canada Neuroendocrine Prostate Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neuroendocrine Prostate Cancer Market

• 31.1. South America Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neuroendocrine Prostate Cancer Market

• 32.1. Brazil Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neuroendocrine Prostate Cancer Market

• 33.1. Middle East Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neuroendocrine Prostate Cancer Market

• 34.1. Africa Neuroendocrine Prostate Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neuroendocrine Prostate Cancer Market Regulatory and Investment Landscape

36. Neuroendocrine Prostate Cancer Market Competitive Landscape And Company Profiles

• 36.1. Neuroendocrine Prostate Cancer Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Neuroendocrine Prostate Cancer Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Neuroendocrine Prostate Cancer Market Company Profiles
  • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Phanes Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. BioXcel Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Global Neuroendocrine Prostate Cancer Market Competitive Benchmarking And Dashboard

38. Upcoming Startups in the Market

39. Key Mergers And Acquisitions In The Neuroendocrine Prostate Cancer Market

40. Neuroendocrine Prostate Cancer Market High Potential Countries, Segments and Strategies

• 40.1 Neuroendocrine Prostate Cancer Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Neuroendocrine Prostate Cancer Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Neuroendocrine Prostate Cancer Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer